Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
222727-43-7
Molecular formula
C5H8FNO2
Molecular weight
133.12 g/mol
Drug class
18F-labelled synthetic amino acid PET radiotracerdiagnostic imaging agent
Mechanism of action
Transported into tumour cells primarily through amino acid transporters such as ASCT2 and LAT1. Increased uptake can identify recurrent prostate cancer tissue after treatment; it is not a therapeutic amino acid analogue.
Indications / reported uses
PET imaging to detect suspected recurrent prostate cancer in adults with rising prostate-specific antigen (PSA) after prior treatment; imaging findings should be interpreted with clinical and other diagnostic data
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Fluciclovine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Fluciclovine Permitted Daily Exposure (PDE) report (the Fluciclovine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Fluciclovine Occupational Exposure Limit (OEL) report (the Fluciclovine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.